Sarepta Therapeutics (SRPT)

$18.02 -0.16 (-0.88%)
Market Cap 1.92B
Revenue (ttm) 2.20B
Net Income (ttm) -713.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 4.78
Profit Margin -32.45%
Debt to Equity Ratio 0.55
Volume 1,600,100
Avg Vol 3,361,728
Day's Range N/A - N/A
Shares Out 105.63M
Stochastic %K 70%
Beta 0.24
Analysts Sell
Price Target $21.96

Company Profile

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dyst...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 274 4000
Address:
215 First Street, Suite 415, Cambridge, United States
No_Body_Knows
No_Body_Knows Aug. 19 at 2:11 PM
$SRPT https://www.nbcnews.com/politics/trump-administration/trump-heidi-overton-fda-commissioner-rcna593309
0 · Reply
KY3000
KY3000 Aug. 19 at 2:10 PM
$SRPT biotechs are 1-3x market cap evaluations, undervalued. Something’s got to give
0 · Reply
monoksop
monoksop Aug. 19 at 2:09 PM
$SRPT On the way
0 · Reply
Valueforall
Valueforall Aug. 19 at 2:09 PM
$SRPT so who bought the dip? And who is throwing the party 🎉 tonight? Honestly I just retired last week and I feel like I just retired again 😆
0 · Reply
JaroSlava77
JaroSlava77 Aug. 19 at 2:02 PM
$SRPT In case you missed it, great news today for gene therapy biotechs> Moderna, Merck Phase 3 trial of mRNA melanoma therapy intismeran plus Keytruda meets primary, key secondary endpoints 😃
0 · Reply
Initiator1
Initiator1 Aug. 19 at 1:56 PM
$SRPT Nice to see this one up today as my semiconductor / AI stocks are getting crushed.
1 · Reply
JDRichie
JDRichie Aug. 19 at 1:56 PM
$SRPT Any idea what is happening?
2 · Reply
KY3000
KY3000 Aug. 19 at 1:56 PM
$SRPT hopefully Roche has data on simulous also
0 · Reply
Agayboy
Agayboy Aug. 19 at 1:54 PM
$SRPT gays bears not haven fun today here
0 · Reply
No_Body_Knows
No_Body_Knows Aug. 19 at 1:44 PM
$SRPT $24 this time!
1 · Reply
Latest News on SRPT
Sarepta Therapeutics Earnings Call Transcript: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 13 days ago

Sarepta Therapeutics Earnings Call Transcript: Q2 2026

Sarepta Therapeutics Quarterly report: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 13 days ago

Sarepta Therapeutics Quarterly report: Q2 2026

Sarepta Therapeutics Earnings release: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 13 days ago

Sarepta Therapeutics Earnings release: Q2 2026

Sarepta Therapeutics Slides: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 13 days ago

Sarepta Therapeutics Slides: Q2 2026

Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments

Aug 5, 2026, 4:05 PM EDT - 13 days ago

Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments

SRPT

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 29, 2026, 5:00 PM EDT - 20 days ago

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SRPT

Sarepta names former Abbvie president as CEO as Ingram retires

Jul 27, 2026, 9:19 AM EDT - 23 days ago

Sarepta names former Abbvie president as CEO as Ingram retires

SRPT

Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer

Jul 27, 2026, 8:30 AM EDT - 23 days ago

Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer

SRPT

Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results

Jul 22, 2026, 8:30 AM EDT - 4 weeks ago

Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results

SRPT

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Sarepta Therapeutics, Inc. (SRPT)

Jul 13, 2026, 9:46 AM EDT - 5 weeks ago

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Sarepta Therapeutics, Inc. (SRPT)

SRPT

Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®

Jun 30, 2026, 8:30 AM EDT - 7 weeks ago

Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®

SRPT

Sarepta Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 8, 2026, 10:40 AM EDT - 2 months ago

Sarepta Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Sarepta Therapeutics Transcript: AGM 2026

Jun 4, 2026, 10:00 AM EDT - 2 months ago

Sarepta Therapeutics Transcript: AGM 2026

Sarepta Therapeutics to Participate in Upcoming Investor Conferences

Jun 1, 2026, 4:30 PM EDT - 2 months ago

Sarepta Therapeutics to Participate in Upcoming Investor Conferences

SRPT

Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference

May 13, 2026, 4:30 PM EDT - 3 months ago

Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference

SRPT

Sarepta Therapeutics Earnings Call Transcript: Q1 2026

May 6, 2026, 4:30 PM EDT - 3 months ago

Sarepta Therapeutics Earnings Call Transcript: Q1 2026

Sarepta Therapeutics Quarterly report: Q1 2026

May 6, 2026, 4:30 PM EDT - 3 months ago

Sarepta Therapeutics Quarterly report: Q1 2026

Sarepta Therapeutics Earnings release: Q1 2026

May 6, 2026, 4:30 PM EDT - 3 months ago

Sarepta Therapeutics Earnings release: Q1 2026

Sarepta Therapeutics Slides: Q1 2026

May 6, 2026, 4:30 PM EDT - 3 months ago

Sarepta Therapeutics Slides: Q1 2026

Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments

May 6, 2026, 4:05 PM EDT - 3 months ago

Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments

SRPT

Sarepta Therapeutics Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 4 months ago

Sarepta Therapeutics Proxy statement: Proxy filing

Sarepta Therapeutics to Announce First Quarter 2026 Financial Results

Apr 22, 2026, 8:30 AM EDT - 4 months ago

Sarepta Therapeutics to Announce First Quarter 2026 Financial Results

SRPT

Sarepta Therapeutics Transcript: Study result

Mar 25, 2026, 8:30 AM EDT - 5 months ago

Sarepta Therapeutics Transcript: Study result

Sarepta Therapeutics Press release: Study result

Mar 25, 2026, 8:30 AM EDT - 5 months ago

Sarepta Therapeutics Press release: Study result

Sarepta Therapeutics Slides: Study result

Mar 25, 2026, 8:30 AM EDT - 5 months ago

Sarepta Therapeutics Slides: Study result

Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1

Mar 25, 2026, 8:05 AM EDT - 5 months ago

Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1

SRPT

Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1

Mar 24, 2026, 4:05 PM EDT - 5 months ago

Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1

SRPT

Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53®

Mar 19, 2026, 8:30 AM EDT - 5 months ago

Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53®

SRPT

Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne

Mar 16, 2026, 8:33 AM EDT - 5 months ago

Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne

SRPT

Sarepta Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 1:50 PM EST - 6 months ago

Sarepta Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program

Feb 27, 2026, 9:00 AM EST - 6 months ago

Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program

SRPT

Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress

Feb 26, 2026, 8:30 AM EST - 6 months ago

Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress

SRPT

Sarepta Therapeutics CEO Ingram to retire by year end

Feb 26, 2026, 5:05 AM EST - 6 months ago

Sarepta Therapeutics CEO Ingram to retire by year end

SRPT

Sarepta Therapeutics Earnings Call Transcript: Q4 2025

Feb 25, 2026, 4:30 PM EST - 6 months ago

Sarepta Therapeutics Earnings Call Transcript: Q4 2025

Sarepta Therapeutics Annual report: Q4 2025

Feb 25, 2026, 4:30 PM EST - 6 months ago

Sarepta Therapeutics Annual report: Q4 2025

Sarepta Therapeutics Earnings release: Q4 2025

Feb 25, 2026, 4:30 PM EST - 6 months ago

Sarepta Therapeutics Earnings release: Q4 2025

Sarepta Therapeutics Slides: Q4 2025

Feb 25, 2026, 4:30 PM EST - 6 months ago

Sarepta Therapeutics Slides: Q4 2025

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments

Feb 25, 2026, 4:05 PM EST - 6 months ago

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments

SRPT

Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan

Feb 24, 2026, 9:07 AM EST - 6 months ago

Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan

SRPT

Sarepta Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 8:30 AM EST - 6 months ago

Sarepta Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

SRPT

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results

Feb 11, 2026, 8:30 AM EST - 6 months ago

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results

SRPT

Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington's Disease

Feb 4, 2026, 8:30 AM EST - 7 months ago

Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington's Disease

SRPT

Sarepta Stock Rises on Positive 3-Year Study Results for Elevidys

Jan 26, 2026, 8:53 AM EST - 7 months ago

Sarepta Stock Rises on Positive 3-Year Study Results for Elevidys

SRPT

Sarepta Therapeutics Transcript: Study result

Jan 26, 2026, 8:30 AM EST - 7 months ago

Sarepta Therapeutics Transcript: Study result

Sarepta Therapeutics Press release: Study result

Jan 26, 2026, 8:30 AM EST - 7 months ago

Sarepta Therapeutics Press release: Study result

Sarepta Therapeutics Slides: Study result

Jan 26, 2026, 8:30 AM EST - 7 months ago

Sarepta Therapeutics Slides: Study result

Sarepta's Duchenne gene therapy helps maintain motor function, three-year data shows

Jan 26, 2026, 8:10 AM EST - 7 months ago

Sarepta's Duchenne gene therapy helps maintain motor function, three-year data shows

SRPT

Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients

Jan 26, 2026, 8:00 AM EST - 7 months ago

Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients

SRPT

Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy

Jan 23, 2026, 4:05 PM EST - 7 months ago

Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy

SRPT

Sarepta Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 12:00 PM EST - 7 months ago

Sarepta Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Sarepta Therapeutics Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 12:00 PM EST - 7 months ago

Sarepta Therapeutics Slides: 44th Annual J.P. Morgan Healthcare Conference

Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues

Jan 12, 2026, 11:58 AM EST - 7 months ago

Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues

SRPT

Johnson Fistel Investigates Sarepta Therapeutics, Inc. (SRPT) Directors for Potential Breaches of Fiduciary Duty

Jan 12, 2026, 9:30 AM EST - 7 months ago

Johnson Fistel Investigates Sarepta Therapeutics, Inc. (SRPT) Directors for Potential Breaches of Fiduciary Duty

SRPT

Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington's Disease

Jan 7, 2026, 8:30 AM EST - 8 months ago

Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington's Disease

SRPT

Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 8:30 AM EST - 8 months ago

Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

SRPT

Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027

Dec 11, 2025, 7:00 AM EST - 8 months ago

Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027

SRPT

Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne

Nov 25, 2025, 8:57 AM EST - 9 months ago

Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne

SRPT

Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics

Nov 24, 2025, 7:30 AM EST - 9 months ago

Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics

ARWR SRPT

Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1

Nov 24, 2025, 7:30 AM EST - 9 months ago

Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1

SRPT

Sarepta Announces FDA's Approval of Updated ELEVIDYS Prescribing Information

Nov 14, 2025, 2:54 PM EST - 9 months ago

Sarepta Announces FDA's Approval of Updated ELEVIDYS Prescribing Information

SRPT

US FDA adds strongest warning to Sarepta gene therapy after fatal liver injuries

Nov 14, 2025, 2:08 PM EST - 9 months ago

US FDA adds strongest warning to Sarepta gene therapy after fatal liver injuries

SRPT

Sarepta Therapeutics shares plunge after disappointing trial data

Nov 4, 2025, 9:55 AM EST - 10 months ago

Sarepta Therapeutics shares plunge after disappointing trial data

SRPT

Sarepta Stock Tumbles 40%. Why the Biotech's Shares Are Sinking.

Nov 4, 2025, 6:20 AM EST - 10 months ago

Sarepta Stock Tumbles 40%. Why the Biotech's Shares Are Sinking.

SRPT

Sarepta slumps as gene therapy setback adds to drug pipeline woes

Nov 4, 2025, 4:27 AM EST - 10 months ago

Sarepta slumps as gene therapy setback adds to drug pipeline woes

SRPT

Sarepta's stock plummets as disappointing trial data raise questions on DMD drug's success

Nov 3, 2025, 6:26 PM EST - 10 months ago

Sarepta's stock plummets as disappointing trial data raise questions on DMD drug's success

SRPT

Sarepta Therapeutics Earnings Call Transcript: Q3 2025

Nov 3, 2025, 4:30 PM EST - 10 months ago

Sarepta Therapeutics Earnings Call Transcript: Q3 2025

Sarepta Therapeutics Quarterly report: Q3 2025

Nov 3, 2025, 4:30 PM EST - 10 months ago

Sarepta Therapeutics Quarterly report: Q3 2025

Sarepta Therapeutics Earnings release: Q3 2025

Nov 3, 2025, 4:30 PM EST - 10 months ago

Sarepta Therapeutics Earnings release: Q3 2025

Sarepta Therapeutics Slides: Q3 2025

Nov 3, 2025, 4:30 PM EST - 10 months ago

Sarepta Therapeutics Slides: Q3 2025

Sarepta's Duchenne gene therapy misses main goal in study

Nov 3, 2025, 4:24 PM EST - 10 months ago

Sarepta's Duchenne gene therapy misses main goal in study

SRPT

Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE

Nov 3, 2025, 4:05 PM EST - 10 months ago

Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE

SRPT

Sarepta Therapeutics to Announce Third Quarter 2025 Financial Results

Oct 27, 2025, 4:05 PM EDT - 10 months ago

Sarepta Therapeutics to Announce Third Quarter 2025 Financial Results

SRPT

Tradr Debuts Leveraged ETFs on BLSH, DASH, FLY, IREN, NEM, OPEN, QS, SRPT & WULF

Oct 23, 2025, 6:46 AM EDT - 10 months ago

Tradr Debuts Leveraged ETFs on BLSH, DASH, FLY, IREN, NEM, OPEN, QS, SRPT & WULF

BLSH DASH FLY IREN NEM OPEN QS

Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2025 World Muscle Society Congress

Oct 3, 2025, 8:30 AM EDT - 11 months ago

Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2025 World Muscle Society Congress

SRPT

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2025-2026 Academic Year

Sep 5, 2025, 9:00 AM EDT - 1 year ago

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2025-2026 Academic Year

SRPT

No_Body_Knows
No_Body_Knows Aug. 19 at 2:11 PM
$SRPT https://www.nbcnews.com/politics/trump-administration/trump-heidi-overton-fda-commissioner-rcna593309
0 · Reply
KY3000
KY3000 Aug. 19 at 2:10 PM
$SRPT biotechs are 1-3x market cap evaluations, undervalued. Something’s got to give
0 · Reply
monoksop
monoksop Aug. 19 at 2:09 PM
$SRPT On the way
0 · Reply
Valueforall
Valueforall Aug. 19 at 2:09 PM
$SRPT so who bought the dip? And who is throwing the party 🎉 tonight? Honestly I just retired last week and I feel like I just retired again 😆
0 · Reply
JaroSlava77
JaroSlava77 Aug. 19 at 2:02 PM
$SRPT In case you missed it, great news today for gene therapy biotechs> Moderna, Merck Phase 3 trial of mRNA melanoma therapy intismeran plus Keytruda meets primary, key secondary endpoints 😃
0 · Reply
Initiator1
Initiator1 Aug. 19 at 1:56 PM
$SRPT Nice to see this one up today as my semiconductor / AI stocks are getting crushed.
1 · Reply
JDRichie
JDRichie Aug. 19 at 1:56 PM
$SRPT Any idea what is happening?
2 · Reply
KY3000
KY3000 Aug. 19 at 1:56 PM
$SRPT hopefully Roche has data on simulous also
0 · Reply
Agayboy
Agayboy Aug. 19 at 1:54 PM
$SRPT gays bears not haven fun today here
0 · Reply
No_Body_Knows
No_Body_Knows Aug. 19 at 1:44 PM
$SRPT $24 this time!
1 · Reply
KY3000
KY3000 Aug. 19 at 1:43 PM
$SRPT hopefully all the collective crying & bitching made a difference, let’s break this 20$ today
1 · Reply
SpanishRetailer
SpanishRetailer Aug. 19 at 1:42 PM
$SRPT Wen 40$? 🤣 Glad to see we don't suck anymore, time to regain 20s and stay there at least a full month between 21-23$ so any good news during Q4 could cause a move to 28-30$ and a couple of analyst upgrades. Still holding a bag between +30% and -20% green to red to green to red to green again and not selling until +40$ Don't mind waiting for Q3-Q4 2027 if needed.
0 · Reply
jm0olah
jm0olah Aug. 19 at 1:42 PM
$SRPT better to be lucky than good
0 · Reply
KingTut
KingTut Aug. 19 at 1:37 PM
$SRPT can it break this key level or not ?
0 · Reply
BiodegradableBurger
BiodegradableBurger Aug. 19 at 1:36 PM
$SRPT I need answers. This can’t be real.
1 · Reply
fpak
fpak Aug. 19 at 1:33 PM
$SRPT Nice. Fake 5% pump is back.
1 · Reply
Moemazon
Moemazon Aug. 19 at 1:00 PM
$SRPT $25.01
0 · Reply
fpak
fpak Aug. 19 at 12:48 PM
$SRPT If Michael was smart he would come with some news today.... Just invent something dude, they all do.
1 · Reply
Valueforall
Valueforall Aug. 19 at 12:09 PM
$SRPT Maybe sarepta’s time is coming if my article from last year comes to fruition
1 · Reply
fpak
fpak Aug. 19 at 11:47 AM
$SRPT To think i sold Moderna to buy this turd. Fml.
2 · Reply
nyzgujuboi89
nyzgujuboi89 Aug. 19 at 11:23 AM
$SRPT wow $MRNA 👀
0 · Reply
Singhbigthings
Singhbigthings Aug. 19 at 11:23 AM
$SRPT close to > 2 bills revenue & increasing, approximately 1 bill cash in hand = 10 billions valuation = $100 stock coming!!
0 · Reply